OptimizeRx Corporation
NASDAQ:OPRXMedical - Healthcare Information Services
-$0.05 today
- Market cap
- $138.21M
- Beta
- 1.10
- P/E (TTM)
- 13.8
- EPS (TTM)
- $0.36
Volume 0.18M
Average 0.47M
OPRX Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
OptimizeRx CorporationNASDAQ: OPRX
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents rises 21.7% from a year ago
Cash & equivalents stood at $20.17M at the end of Q1 FY2026, up 21.7% from a year earlier and down 13.7% from the prior quarter. Over 3 fiscal years it compounded at +8.7% a year.
Context
- Cash & equivalents amounted to 12.1% of total assets at the end of Q1 FY2026, up 2.2 pp from a year earlier.
- Cash & equivalents increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +21.7% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 23.37M USD
- Year-over-year change
- +74.6%
- 4-year CAGR
- -27.5%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 23.37M | +74.6% |
| FY2024 | 2024-12-31 | 13.38M | -3.4% |
| FY2023 | 2023-12-31 | 13.85M | -23.9% |
| FY2022 | 2022-12-31 | 18.21M | -78.5% |
| FY2021 | 2021-12-31 | 84.68M | — |
Cash & Equivalents vs competitors
How OPRX compares with its peers on the latest reported figures
- Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +21.7% is the 6th highest of 10, against a peer median of +48.6%.
- Cash & equivalents amounts to 12.1% of total assets for OPRX, versus a peer median of 8.8%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | CA$309.3M CAD | +455.5% | +92.5% | 99.1% | |
| Mar 2026 | $157.65M USD | +48.6% | +3.7% | 30.6% | |
| Mar 2026 | $65.39M USD | -4.6% | -24.2% | 41.7% | |
| Mar 2026 | $35.42M USD | +249.9% | +52.9% | 8.7% | |
| Mar 2026 | $35.3M USD | +2994.9% | +394.4% | 5.7% | |
| Feb 2026 | $25.73M USD | +134.1% | -15.7% | 17.6% | |
| Mar 2026 | $20.17M USD | +21.7% | +8.7% | 12.1% | |
| Mar 2026 | $17.57M USD | -37.2% | +19.0% | 5.8% | |
| Mar 2026 | $17.08M USD | -14.1% | -10.9% | 8.8% | |
| Mar 2026 | $2.55M USD | +1.8% | -45.1% | 1.9% | |
| Peer median (excluding OPRX) | — | +48.6% | +3.7% | 8.8% | |
Competitors are the stored peer set for OPRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 84.68M | 18.21M | 13.85M | 13.38M | 23.37M |
| Short-term Investments | 0 | 55.93M | 0 | 0 | 0 |
| Net Receivables | 24.8M | 22.16M | 37.29M | 38.21M | 37.75M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 608.15K | 473.65K | 404.47K | 387K | 752K |
| Total Current Assets | 115.11M | 98.58M | 54.33M | 53.97M | 64.72M |
| Property, Plant & Equipment (Net) | 472.64K | 372.77K | 722.3K | 516K | 510K |
| Goodwill | 14.74M | 22.67M | 78.36M | 70.87M | 70.87M |
| Intangible Assets | 10.65M | 13.02M | 49.4M | 45.52M | 40.8M |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 12.86K | 5.05K | 568.05K | 296K | 28K |
| Total Non-current Assets | 25.87M | 36.07M | 129.04M | 117.2M | 112.2M |
| Total Assets | 140.99M | 134.65M | 183.37M | 171.17M | 176.92M |
| Account Payables | 606.81K | 1.55M | 2.23M | 2.16M | 1.64M |
| Short-term Debt | 0 | 0 | 2M | 2M | 4.26M |
| Tax Payables | 0 | 0 | 49K | 318K | 0 |
| Deferred Revenue | 1.39M | 164.31K | 171.84K | 473K | 503K |
| Other Current Liabilities | 0 | 0 | 5.55M | 0 | 3.09M |
| Total Current Liabilities | 9.37M | 8.4M | 17.88M | 18.65M | 21.26M |
| Long-term Debt | 0 | 0 | 34.23M | 30.82M | 21.42M |
| Deferred Tax Liabilities | 0 | 0 | 4.34M | 4.49M | 5.71M |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 236.73K | 144.53K | 38.94M | 35.52M | 27.36M |
| Total Liabilities | 9.61M | 8.54M | 56.82M | 54.17M | 48.62M |
| Common Stock | 17.86K | 18.29K | 19.9K | 20K | 20K |
| Retained Earnings | (35.25M) | (46.69M) | (64.26M) | (84.37M) | (79.24M) |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 131.38M | 126.11M | 126.55M | 117M | 128.29M |
| Total Debt | 327.71K | 234.43K | 36.82M | 33.19M | 26.1M |
| Net Debt | (84.35M) | (17.97M) | 22.97M | 19.81M | 2.74M |
OptimizeRx Corporation
NASDAQ:OPRX
Intrinsic Alpha fair value
Locked
Current Price
$7.31
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.